Alliance A091304: A Phase I/ Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma

Objective

This partially randomized phase I/II trial studies the side effects and best dose of sapanisertib and to see how well it works compared to pazopanib hydrochloride in treating patients with sarcoma that is too large to be removed (locally advanced) or has spread to other areas of the body (metastatic). Sapanisertib and pazopanib hydrochloride both work to stop the growth of tumor cells by blocking enzymes that are needed for cell growth. It is not yet known whether sapanisertib may be more effective than standard treatment with pazopanib hydrochloride in treating patients with locally advanced or metastatic sarcoma.

https://www.clinicaltrials.gov/ct2/show/NCT02601209

Contact Phone: 218-786-3308 | 1-844-681-7944

Email: cancertrials@essentiahealth.org

Locations: Essentia Health Cancer Centers

Disclosures:

None

For more information about a financial conflict of interest (FCOI), review the Essentia Health FCOI policy.

Last Updated: 06/08/2018

Research Study Categories

  • Adult Studies

Specialty

  • Sarcoma
  • Cancer